Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
HB0028
/
Zhejiang Huahai Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
HB0028
/
Zhejiang Huahai Pharma
A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.
(Hall A; Poster Bd #: 7) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2932;
P1/2
HB0028 was generally well tolerated, and therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. Based on these data, a phase II prospective clinical trial is being planned in specific cancer.